Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naïve patients with unresectable malignant pleural mesothelioma

BACKGROUND: We conducted a phase I trial of cisplatin-pemetrexed-imatinib mesylate, an oral PDGFR inhibitor, in chemo-naive MPM patients. METHODS: A standard 3+3 dose-escalating trial was used with the endpoints of MTD, response rate, survival, safety/toxicity and tumor PDGFR levels. RESULTS: 17 MPM...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Lung Cancer
Auteurs principaux: Tsao, AS, Harun, N, Lee, J.J, Heymach, J, Pisters, K, Hong, WK, Fujimoto, J, Wistuba, I
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5080907/
https://ncbi.nlm.nih.gov/pubmed/24492162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2013.12.008
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires